ASCORBIC ACID - MODULATION OF ARSENIC TRIOXIDE TOXICITY: IMPLICATION FOR THE CLINICAL TREATMENT OF ACUTE...

Area of Science:

• Hematology
• Oncology
• Biochemistry

Background:

• Acute Promyelocytic Leukemia (APL) is a distinct subtype of acute leukemia.
• Arsenic trioxide (ATO) has demonstrated efficacy in inducing remission for APL patients.
• Ascorbic acid (AA), an antioxidant, has a complex role, potentially acting as a pro-oxidant in certain contexts.

Purpose of the Study:

• To investigate the modulatory effects of ascorbic acid (AA) on arsenic trioxide (ATO)-induced oxidative stress in leukemia cells.
• To determine if AA can enhance the anti-leukemic activity of ATO.

Main Methods:

• Cell viability was assessed using MTT assay and trypan blue exclusion.
• Malondialdehyde (MDA) production, an indicator of lipid peroxidation, was measured using the thiobarbituric acid test.
• HL-60 leukemia cells were co-exposed to varying concentrations of AA and ATO.

Main Results:

• Ascorbic acid (AA) potentiated the cytotoxic effects of arsenic trioxide (ATO) on HL-60 cells.
• Increased levels of malondialdehyde (MDA) were observed with combined AA and ATO treatment, indicating enhanced oxidative stress.
• Ascorbic acid addition amplified the formation of reactive oxygen species (ROS) in ATO-treated leukemia cells.

Conclusions:

• Ascorbic acid (AA) enhances arsenic trioxide (ATO)-induced oxidative stress and cytotoxicity in leukemia cells.
• The findings suggest that AA may broaden the therapeutic potential of ATO.
• Combining AA with ATO could potentially improve clinical outcomes in APL treatment.